Treatments have included both the gene and protein vectors of pigment epithelium-derived factor (PEDF) to inhibit choroidal neovascularisation (CNV) 75, 76, whilst others have transfected RPE with growth factor-β2 (GF-β2) and platelet-derived growth factor-B (PDGF-B) plasmids to attenuate proliferative vitreoretinopathy 34. This evidence concerns the gene SERPINF1 and proliferative vitreoretinopathy.